Business Context and Reporting Period
Revelation Biosciences, Inc. (REVB) is a clinical-stage biopharmaceutical company developing therapeutics based on its proprietary formulation, Gemini, to harness trained immunity. The company is focused on three primary programs: GEM-AKI (acute kidney injury), GEM-CKD (chronic kidney disease), and GEM-PSI (post-surgical infection). This Form 10-Q covers the quarterly period ended June 30, 2024. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(11,071,252) | $4,711,025 (Net Income) |
| Operating Expenses | $4,424,535 | $3,552,877 |
| Cash and Cash Equivalents (End of Period) | $12,073,058 | $15,711,218 |
| Net Cash Used in Operating Activities | $(5,316,651) | $(3,566,769) |
| Net Cash Provided by Financing Activities | $5,417,180 | $14,025,008 |
| Total Liabilities | $11,129,154 | $5,564,894 |
| Stockholders' Equity | $1,140,421 | $11,414,803 |
Material Changes vs. Prior Period
- Net Loss vs. Net Income: The company reported a net loss of $11.1 million for the six months ended June 30, 2024, compared to net income of $4.7 million in the same period in 2023. This reversal is primarily driven by a $7.5 million legal judgment and related costs (detailed below) and a reduction in the gain from the change in fair value of warrant liabilities.
- Operating Expenses: Total operating expenses increased by $871,658 (24.5%) year-over-year. Research and Development (R&D) expenses rose by $677,960, driven by $1.3 million in clinical study expenses for GEM-AKI and GEM-PSI. General and Administrative (G&A) expenses increased by $193,698, primarily due to higher personnel costs.
- Other (Expense) Income: Total other expense increased significantly to $(6.6) million from income of $8.3 million in the prior year. The 2023 period included an $8.2 million gain from the change in fair value of warrant liabilities, whereas the 2024 period included a $7.5 million expense related to the LifeSci Capital LLC judgment.
- Liquidity: Cash balances decreased by approximately $3.6 million year-over-year, despite raising $5.4 million in a February 2024 public offering. The decrease is attributed to higher operating cash burn and the settlement of legal liabilities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With $12.1 million in cash and an operating burn rate of approximately $5.3 million over six months, the company does not anticipate its current resources will sustain operations for one year from the filing date. Additional equity or debt financing is required.
- Legal Judgment (Unusual Item): On August 1, 2024, a District Court judge granted summary judgment in favor of LifeSci Capital LLC, issuing a judgment totaling $7.3 million plus interest, with an additional $0.2 million in cost reimbursement. Approximately $5.8 million of this amount was expensed in the current period, significantly impacting the net loss. The total liability is recorded in accrued expenses.
- Capital Raising: The company closed a public offering in February 2024, raising net proceeds of $5.4 million. The company plans to seek additional funding through public or private equity or debt financings to continue development.
- Reverse Stock Split: A 1-for-30 reverse stock split was effected on January 25, 2024. All share and per-share data in this filing reflect this split.
- Outlook: The company expects to continue incurring significant operating losses as it advances clinical trials for its product candidates. No revenue is expected until regulatory approval is obtained, which is not anticipated for several years, if ever.
Investor Verification Checklist
- Legal Liability Status: Verify the payment status of the $7.5 million LifeSci Capital LLC judgment and any potential appeals or further cost motions.
- Cash Runway: Assess the sufficiency of the $12.1 million cash balance against the current burn rate and the timeline for securing additional financing.
- Warrant Liability Volatility: Monitor the fair value of outstanding warrant liabilities (Class C and Class D), as changes in fair value continue to impact the income statement.
- Clinical Trial Progress: Review updates on the GEM-AKI and GEM-PSI clinical studies, which are the primary drivers of the increased R&D spend.
- Dilution Risk: Evaluate the impact of potential future equity raises on existing shareholders, given the company's need for capital and the existing warrant overhang.